life scienc tool diagnost
ep top consensu abc ep beat
higher revenu profit factor line ad
rais ep guidanc
midpoint reflect oper beat line
factor contribut lift ep
reflect out-performance lower tax rate share count
well continu momentum balanc year tp
move higher view
revenu profit impress revenu improv vs estimate
distribut incl specialti acquisit rise essenti line
view vs estimate rose well ahead plan
repres profit compon posit thesi gross
margin flat y/i bp plan oper expens bp
bp better plan ebit margin rose bp
bp plan focu area oper profit distribut climb
well estimate gener million cash fund
million share repurchas million dividend
share climb share rise rel clean print
beat rais support strong underli core pharma distribut
oper perform alongsid acceler profit contribut
profit segment beat street rais
guidanc midpoint support part line item
underli distribut profit dynam call area exceed
expect potenti implications/opportun light new drug
import scenario maintain posit thesi
view distributor better posit rel peer predic
driver larg pharmaci relationship contribut non-cor unit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
price jul rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
compani mention price
